Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST 261 modified-release tablets for mild ulcerative colitis
NL-OMON37764Phase 3Active, not recruiting
- Sponsor
- Leadiant Biosciences
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of propionyl-L-carnitine in autoimmune colitis, sponsored by Leadiant Biosciences. Primary endpoints: Clinical/endoscopic remission at end of treatment and Safety and tolerability. Started Mar 2013; status: active, not recruiting.
02
Drugs
propionyl-L-carnitine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON37764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37764.